Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364846 | 1.00 | DPP4 (0.43) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL28759095 | 1.00 | DPP4 (0.43) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL342707 | 1.00 | DPP4 (0.43) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL27791284 | 0.91 | DPP4 (0.40) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL571933 | 0.91 | CTSS (0.41) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL10057576 | 0.91 | CTSS (0.41) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL1509212 | 0.90 | AAK1 (0.45) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL2364292 | 0.90 | AAK1 (0.45) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL344600 | 0.90 | DPP4 (0.43) | DPP4ATMCTSSCTSKAAK1 | |
| SCHEMBL19500634 | 0.90 | DPP4 (0.43) | DPP4ATMCTSSCTSKAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119019471-A | Fluorine-containing cytidine guanidine compound, and preparation method and application thereof | 沈阳农业大学 | 2024-11-26 | — | — | CN | claimed |
| CN-113121540-B | Synthesis method of sitagliptin free alkali | 鲁南制药集团股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115385919-A | Synthetic method of sitagliptin | 江苏阿尔法药业股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-109096133-B | 3-amino-4- (2,4, 5-trifluorophenyl) menthyl butyrate hydrochloride and preparation method and application thereof | 宁波职业技术学院 | 2022-06-07 | — | — | CN | claimed |
| CN-113121540-A | Synthesis method of sitagliptin free alkali | 鲁南制药集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-9233967-B2 | Process for the preparation of sitagliptin and intermediate compounds | CIPLA LIMITED (IN) | 2016-01-12 | — | — | US | claimed |
| US-20150197523-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | CIPLA LIMITED (IN) | 2015-07-16 | — | — | US | claimed |
| EP-2882752-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | Cipla Limited (IN) | 2015-06-17 | — | — | EP | claimed |
| WO-2014086325-A1 | A METHOD OF PREPARING 3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOIC ACID DERIVATIVES | ZENTIVA, K.S. (CZ) | 2014-06-12 | — | — | WO | claimed |
| WO-2014023930-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | CIPLA LIMITED (IN) | 2014-02-13 | — | — | WO | claimed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | claimed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | claimed |
| WO-2009064476-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-22 | — | — | WO | claimed |
| CN-119698278-A | Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2025-03-25 | — | — | CN | disclosed |
| CN-119019471-A | Fluorine-containing cytidine guanidine compound, and preparation method and application thereof | 沈阳农业大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-118908861-A | Preparation method of Boc- (R) -3-amino-4- (2, 4, 5-trifluorophenyl) butyric acid, intermediate I and preparation method thereof | 台州达辰药业有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-1583534-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1554280-A2 | ANTIDIABETIC BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS | Merck & Co., Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004058266-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004032836-A2 | ANTIDIABETIC BETA-AMINO HETEROCYLCIC DIPEPTIDYL PEPTIDASE INHIBITORS | MERCK & CO., INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | DPP4, DPP7, DPP3 | DPP4 1/4885ATM 2081/4885CTSS 1611/4885 |
| US-20150197523-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | DPP4, DPP7, DPP9 | DPP4 1/4885ATM 3694/4885CTSS 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.